We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
Firalis creates novel values via biomarker discovery, development and regulatory qualification and brings to market biomarker-based diagnostic products for neurodegenerative disorders and cardiovascular diseases. With a comprehensive expertise in the field, Firalis provides an extensive range of biomarker services to support clinical studies & research.
Quanterix™ Corporation is digitizing biomarker analysis with the goal of advancing the science of precision healthcare. Our ultra-sensitive technology platform, Simoa®, enables researchers to quantify a range of disease biomarkers at lower levels than ever before, in most common sample types. Simoa’s ultra-sensitivity, multiplex detection capability and flexibility in custom assay development are advancing both academic research and drug development both in our customers' own facilities and by contract in our CLIA-certified Quanterix Accelerator Laboratory.
At Biognosys, we believe that proteome insights unfold breakthrough discoveries that can dramatically improve human health. With our versatile portfolio of proprietary next-generation proteomics services, software, and kits, we provide a multi-dimensional view of protein expression, function, and structure in all sample types. Our patented technologies utilize high-resolution mass spectrometry, and through advanced data analytics, we translate data into actionable insights for R&D and clinical research.
Swedish company Olink Proteomics provides the most efficient tool available for targeted human protein biomarker discovery, development and implementation, with high-throughput analysis, exceptional data quality, and minimal sample consumption. Disease or biological process-focused panels are available, with full transparency on our rigorous validation data. The current library enables rapid analysis of over 1,000 validated protein biomarkers with less than 15 µl of sample. Olink panels are available via our Analysis Service or as kits.
Hawk Biosystems have developed a bioimaging assay, QF-Pro®, which is able to quantify protein post-translational modifications and protein-protein interactions within patient pathology samples. This unveils a complete novel family of biomarkers which will change the paradigm of precision medicine. QF-Pro® has been validated in numerous publications where it has elucidated Protein Kinase B (PKB) as a predictive biomarker in renal and breast cancer. Recently, we determined that the interaction state of the immune checkpoint PD-1/PD-L1, determined by QF-Pro® (rather than the expression of PD-L1 alone) is predictive of patient outcome and treatment response. QF-Pro® holds the potential to stratify patients for these advanced immunotherapies. This technology can be applied to a wide range of other pathologies and biomarkers.
Hawk Biosystems are now developing their next release of the QF-Pro® automated bioimaging device, Violet 3.0, which will be able to translate this technology to various research organisations and the clinic.
Metabolon, Inc., reveals biological insights otherwise unseen. Over nearly two decades, Metabolon has built the best metabolomic competency in the world. Today, Metabolon enables, accelerates and supports drug development through biomarker discovery, understanding mechanism of action, patient stratification, and more, as evidenced by >2,000 publications, numerous high-impact case studies and customer testimonials.
Metabolon’s scalable, customizable metabolomics solutions support discovery through clinical trials and product life-cycle management. Metabolon’s diverse patient data set is equipped to deliver biologically relevant insights to address some of the most challenging and pressing questions in the life sciences. Metabolon is ISO 9001:2015 certified for analytical and diagnostic testing of biological specimens, certified by CLIA and accredited by the College of American Pathologists for diagnostic testing on human specimens. The company, founded in 2000, is based in Research Triangle Park, North Carolina. For more information, please visit www.metabolon.com